Related Experiment Video

Updated: May 26, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Pharmacogenomics in pulmonary arterial hypertension: Toward a mechanistic, target-based approach to therapy

Sami I Said1, Sayyed A Hamidi

  • 1Department of Medicine, State University of New York at Stony Brook, and Department of Veterans Affairs Medical Center, Northport, New York, USA.

Pulmonary Circulation
|December 6, 2011
PubMed

Insights

Pharmacogenomics shows promise for pulmonary arterial hypertension (PAH) treatment. Genetic analysis in PAH models revealed how drug response varies, guiding personalized therapy selection.

Area of Science:

  • Pharmacogenomics and Precision Medicine
  • Cardiovascular Research
  • Pulmonary Hypertension

Background:

  • Pharmacogenomics, the study of genetic variations influencing drug response, has advanced cancer treatment.
  • Pulmonary Arterial Hypertension (PAH) presents complex challenges in treatment efficacy and toxicity.
  • Understanding genetic underpinnings is crucial for developing targeted PAH therapies.

Purpose of the Study:

  • To evaluate the applicability of pharmacogenomics in understanding and treating Pulmonary Arterial Hypertension (PAH).
  • To compare the genetic alterations and drug responses in two distinct experimental models of PAH.
  • To investigate the potential of Vasoactive Intestinal Peptide (VIP) as a targeted therapy based on genetic profiles.

Main Methods:

  • Utilized two experimental models for PAH: Vasoactive Intestinal Peptide gene knockout mice (VIP(-/-)) and monocrotaline (MCT)-induced rat model.
  • Analyzed gene expression profiles focusing on pathways of vasoconstriction, vascular remodeling, and inflammation.
  • Assessed the phenotypic and genotypic responses to VIP treatment in both PAH models.

Main Results:

  • VIP(-/-) mice showed overexpression of vasoconstrictive/inflammatory genes and underexpression of vasodilatory genes; VIP treatment fully corrected these and PAH features.
  • MCT-treated rats exhibited mixed genetic alterations, with some promoting disease and others attempting modulation; VIP treatment incompletely corrected phenotypes and genotypes.
  • Demonstrated a correlation between specific genetic profiles, disease progression, and therapeutic outcomes in PAH models.

Conclusions:

  • Genomic information is critical for predicting therapeutic outcomes and personalizing PAH treatment strategies.
  • Pharmacogenomics offers a promising framework for developing more effective and individualized PAH therapies.
  • Further validation in human patients is necessary to fully establish the clinical utility of pharmacogenomics in PAH.
Keywords:
gene analysispharmacogenomicspulmonary arterial hypertensiontargeted therapy of pulmonary arterial hypertension

More Related Videos

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...